Sirolimus
Back to searchMolecule Structure
Scientific Name
Sirolimus
Description of the Drug
Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00877
http://www.drugbank.ca/drugs/DB00877
Brand Name(s)
Fyarro, Hyftor, Rapamune, Sirolimus
Company Owner(s)
Apotex Inc, Nobelpharma Co Ltd, Alkem Laboratories Ltd, Novitium Pharma Llc, Torrent Pharma Inc, Glenmark Pharmaceuticals Ltd, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals Llc, Zydus Pharmaceuticals Usa Inc, Pf Prism Cv
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| FK506-binding protein 1A | SINGLE PROTEIN | INHIBITOR | CHEMBL1902 |
Clinical Trial(s)
Unichem Links
| Atlas | sirolimus | rapamycin | ||||
| SureChEMBL | SCHEMBL3463 | |||||
| Human Metabolome Database | HMDB0015015 | |||||
| DrugBank | DB00877 | |||||
| PubChem: Thomson Pharma | 14816423 | 14816426 | ||||
| PubChem | 5284616 | |||||
| NMRShiftDB | 60027859 | |||||
| LINCS | LSM-42782 | |||||
| PDBe | RAP | |||||
| BindingDB | 36609 | 50064359 | ||||
| EPA CompTox Dashboard | DTXSID5023582 | |||||
| LipidMaps | LMPK06000003 | |||||
| DrugCentral | 2446 | |||||
| Metabolights | MTBLC9168 | |||||
| Brenda | 229857 | 230092 | 229856 | 133748 | 196831 | 230093 |
| Guide to Pharmacology | 6031 | |||||
| rxnorm | SIROLIMUS | RAPAMUNE | ||||
| PubChem: Drugs of the Future | 12014635 | |||||
| KEGG Ligand | C07909 | |||||
| ChEBI | 9168 | |||||
| ZINC | ZINC000169289388 |
